In summary, treatment with GVAX (with low-dose Cy) alone or in combination with PD-1 blockade and CD137 agonist mAb was feasible and safe in patients with resectable PDA treated in the neoadjuvant and adjuvant settings. The gene discussed is TNFRSF9; the disease is Patent ductus arteriosus.